| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.01 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | -0.08 | 0.02 |
| mRNA | Topotecan | FIMM | pan-cancer | AAC | -0.25 | 0.02 |
| mRNA | bendamustine | CTRPv2 | pan-cancer | AAC | 0.089 | 0.02 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.02 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.078 | 0.02 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | 0.073 | 0.02 |
| mRNA | pifithrin-mu | CTRPv2 | pan-cancer | AAC | 0.079 | 0.02 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | 0.079 | 0.02 |